ESA Labeling Should Explain Hemoglobin Target, Advisory Committee Says
Executive Summary
Treatment targets for erythropoiesis-stimulating agents in the renal setting need to be accompanied by clinical management information, FDA's Cardiovascular and Renal Drugs and Drug Safety and Risk Management Advisory Committees says
You may also be interested in...
Amidst ESA Upheaval, FDA Used Mircera Review To Outline Trial “Wish List”
FDA's review of Roche's Mircera BLA became a forum for the agency to set forth a "wish list" for future development of erythropoietin stimulating agents that reflected the seismic upheavals in the conventional understanding of the safety of erythropoietin products
Amidst ESA Upheaval, FDA Used Mircera Review To Outline Trial “Wish List”
FDA's review of Roche's Mircera BLA became a forum for the agency to set forth a "wish list" for future development of erythropoietin stimulating agents that reflected the seismic upheavals in the conventional understanding of the safety of erythropoietin products
Amgen, J&J Propose New Target Range For Aranesp, Procrit
Just a year after FDA removed information related to a dosing target range for erythropoiesis-stimulating agents from product labeling, Amgen and Johnson & Johnson are proposing to re-establish a specific hemoglobin target range for the anemia therapies